Electrophysiological Effects of MS-551 , a New Class III Agent : Comparison with dl-Sotalol in Dogs 1

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• AN ANALYSIS OF THE TIME‐RELATIONS OF ELECTROCARDIOGRAMS.

  1997cited by this paper
• Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.

  1997cited by this paper
• Can a class III antiarrhythmic drug improve electrical defibrillation efficacy during ventricular fibrillation?

  1997cited by this paper
• IK independent class III actions of MS‐551 compared with sematilide and dofetilide during reperfusion in anaesthetized rats

  1996cited by this paper
• Comparison of direct negative chronotropic and positive inotropic effects of sematilide to those of E-4031 and MS-551 and the reverse frequency-dependent prolongation of cardiac refractoriness of sematilide.

  1996cited by this paper
• The coming of age of the class III antiarrhythmic principle: retrospective and future trends.

  1996cited by this paper
• Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

  1996cited by this paper
• Electrophysiological Effects of MS‐551 in Humans: A Class III Antiarrhythmic Agent

  1995cited by this paper
• Effects of the new class III antiarrhythmic drug MS-551 and d-sotalol on canine coronary ligation-reperfusion ventricular arrhythmias.

  1995cited by this paper
• Positive and negative inotropic effects of DL-sotalol and D-sotalol in failing and nonfailing human myocardium under physiological experimental conditions.

  1995cited by this paper
• A new class III antiarrhythmic drug, MS-551, blocks the inward rectifier potassium channel in isolated guinea pig ventricular myocytes.

  1995cited by this paper
• Beta-adrenergic blocking property of dl-sotalol maintains class III efficacy in guinea pig ventricular muscle after isoproterenol.

  1995cited by this paper
• A Comparison of Seven Antiarrhythmic Drugs in Patients with Ventricular Tachyarrhythmias

  1994cited by this paper
• Effects of amiodarone, sematilide, and sotalol on QT dispersion.

  1994influential reference
• Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents.

  1993cited by this paper
• Five-year follow-up of 589 patients treated with amiodarone.

  1993cited by this paper
• Effects of MS‐551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes

  1993cited by this paper
• Frequency-dependent electrophysiologic effects of amiodarone in humans.

  1993cited by this paper
• The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators.

  1993cited by this paper
• Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia.

  1992cited by this paper
• Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias.

  1990cited by this paper
• A new single catheter technique for simultaneous measurement of action potential duration and refractory period in vivo.

  1990cited by this paper
• Rate‐Dependent Class III Antiarrhythmic Action, Negative Chronotropy, and Positive Inotropy of a Novel Ik Blocking Drug, UK‐68,798: Potent in Guinea Pig but no Effect in Rat Myocardium

  1990cited by this paper
• Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence.

  1990cited by this paper
• Antagonism of quinidine's electrophysiologic effects by epinephrine in patients with ventricular tachycardia.

  1988cited by this paper
• Controlled trial of sotalol for one year after myocardial infarction.

  1982cited by this paper
• A simple technique for production of chronic complete heart block in dogs.

  1968cited by this paper

• Negative lusitropic property of nifekalant identified using ventricular pressure-volume loop analyses in anesthetized monkeys

  2018influential citation
• Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation

  2017cites this paper
• Electrophysiologic effects of the IK 1 inhibitor PA‐6 are modulated by extracellular potassium in isolated guinea pig hearts

  2017cites this paper
• Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest.

  2016cites this paper
• Pharmacological inhibition of IK 1 by PA‐6 in isolated rat hearts affects ventricular repolarization and refractoriness

  2016cites this paper
• Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation

  2014cites this paper
• Pharmacoelectrophysiology of viral-free induced pluripotent stem cell-derived human cardiomyocytes.

  2013cites this paper
• Report from J-PULSE multicenter registry of patients with shock-resistant out-of-hospital cardiac arrest treated with nifekalant hydrochloride.

  2010cites this paper
• Prevention of Life-Threatening Ventricular Tachyarrhythmia by a Novel and Pure Class-III Agent, Nifekalant Hydrochloride

  2006influential citation
• Reduced Inotropic Effect of Nifekalant in Failing Hearts in Rats

  2006cites this paper
• Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation.

  2006cites this paper
• Comparison of efficacy of sotalol and nifekalant for ventricular tachyarrhythmias.

  2006cites this paper
• Clinical Comparison of Ibutilide and Propafenone for Converting Atrial Flutter

  2005cites this paper
• Effect of nifekalant, a class III anti-arrhythmic agent, on Ca2+ waves in rat intact trabeculae.

  2005cites this paper
• Electropharmacological and Proarrhythmic Effects of a Class III Antiarrhythmic Drug Nifekalant Hydrochloride Assessed Using the In Vivo Canine Models

  2004cites this paper
• Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction.

  2001cites this paper
• Efficiency, efficacy, and adverse effects of adenovirus vs. liposome-mediated gene therapy in cardiac allografts.

  2001cites this paper
• Effects of Sotalol on the Circadian Rhythmicity of Heart Rate and QT Intervals With a Noninvasive Index of Reverse-Use Dependency

  1999cites this paper